Yasheng Pharmaceutical-B (06855): David Sidransky will be appointed as Chief Independent Non-Executive Director

According to Zhitong Finance App, Yasheng Pharmaceutical-B (06855) announced that Dr. Debra Yu will be appointed as an additional member of the Board Nomination Committee with effect from December 26, 2025.

Dr. David Sidransky will be appointed as the chief independent non-executive director, effective from December 26, 2025, to (i) act as an intermediary between other directors and the Company's shareholders; and (ii) be able to contact other directors and shareholders of the Company if normal communication channels with the Chairman of the Board of Directors or the Company's management are insufficient.

The Board R&D Committee will be established with effect from December 26, 2025. The R&D committee should be composed of scientists, doctors, and business experts to oversee R&D strategies, product lines, investments, and emerging trends to ensure consistency with the business while managing risk. The R&D committee will be chaired by Dr. Marc E. Lippman, MD, and Dr. David Sidransky and Dr. Wang Shaomeng as members.